Nature Communications (Aug 2018)
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
- Rajeswara Rao Arasada,
- Konstantin Shilo,
- Tadaaki Yamada,
- Jianying Zhang,
- Seiji Yano,
- Rashelle Ghanem,
- Walter Wang,
- Shinji Takeuchi,
- Koji Fukuda,
- Nobuyuki Katakami,
- Keisuke Tomii,
- Fumitaka Ogushi,
- Yasuhiko Nishioka,
- Tiffany Talabere,
- Shrilekha Misra,
- Wenrui Duan,
- Paolo Fadda,
- Mohammad A. Rahman,
- Patrick Nana-Sinkam,
- Jason Evans,
- Joseph Amann,
- Elena E. Tchekneva,
- Mikhail M. Dikov,
- David P. Carbone
Affiliations
- Rajeswara Rao Arasada
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Konstantin Shilo
- Department of Pathology, The Ohio State University Medical Center
- Tadaaki Yamada
- Division of Medical Oncology, Kanazawa University Cancer Research Institute
- Jianying Zhang
- Center for Biostatistics, The Ohio State University Medical Center
- Seiji Yano
- Division of Medical Oncology, Kanazawa University Cancer Research Institute
- Rashelle Ghanem
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Walter Wang
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Shinji Takeuchi
- Division of Medical Oncology, Kanazawa University Cancer Research Institute
- Koji Fukuda
- Division of Medical Oncology, Kanazawa University Cancer Research Institute
- Nobuyuki Katakami
- Division of Integrated Oncology, Institute of Biomedical Research and Innovation
- Keisuke Tomii
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital
- Fumitaka Ogushi
- Division of Pulmonary Medicine, National Hospital Organization National Kochi Hospital
- Yasuhiko Nishioka
- Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University
- Tiffany Talabere
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Shrilekha Misra
- Department of Internal Medicine, The Ohio State University Medical Center
- Wenrui Duan
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Paolo Fadda
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Mohammad A. Rahman
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine and the Center for Critical Care Medicine, The Ohio State University Medical Center
- Patrick Nana-Sinkam
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine and the Center for Critical Care Medicine, The Ohio State University Medical Center
- Jason Evans
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Joseph Amann
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Elena E. Tchekneva
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- Mikhail M. Dikov
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- David P. Carbone
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center
- DOI
- https://doi.org/10.1038/s41467-018-05626-2
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Treatment of EGFR mutant non-small cell lung cancer (NSCLC) often develops resistance to EGFR TKIs. In this study, the authors discover a non-canonical activation of β-catenin signaling through Notch3 as a mechanism of adaptation to and resistance to EGFR TKI treatment in NSCLC.
